Phase 3 Readout
ENSC: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet
November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- November 1, 2026
- Company
- Ensysce Biosciences Inc. (ENSC)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet
- Indication
- Postoperative Pain, Acute